What you need to know about opioid overdose reversal drug nalmefene’s risks, effectiveness and clinical concerns ...

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...

Cash Position & Operating Runway : As of December 31, 2024, ARS Pharma had cash, cash equivalents, and short-term investments of $314.0 million, with 97,954,172 shares of common stock outstanding. The ...

Paratek Pharmaceuticals to acquire Optinose and its nasal drug-device Xhance for up to $330M, expanding beyond antibiotics ...

The start of spring kicks off a nasal nuisance for many people, but one drug meant to clear congestion has struggled to do ...

ASX pharmaceutical companies are retaining their assets longer and advancing them to commercialisation in a bid to maximise ...

Eli Lilly, Adaptimmune, Aurion Biotech, and ImmunityBio had breakthrough medicines and therapies debut in the past year.

In NYC, spring kicks off tree pollen season, followed by grass pollen in the summer and weed pollen in the late summer and ...

These studies will assess key parameters, such as drug loading capacity, release kinetics, nasal deposition and stability ... The Naloxone intranasal spray market alone is expected to reach $1.4 ...

Up to 40% of people who suffer from depression are unable to find any relief for their condition. But now, Blessing ...

The FDA is reviewing the supplemental NDA for cabozantinib in adults ... STS101 is an investigational dihydroergotamine (DHE) nasal powder product that is administered via a proprietary nasal delivery ...